LIN SUE-JEAN 4

What Happened

• Lin Sue‑Jean, a non‑employee director of Arcutis Biotherapeutics (ARQT), received equity awards on June 5, 2026: 5,778 restricted stock units (RSUs) and 16,667 derivative awards (total 22,445 units). Both awards were granted at $0.00 per share (no cash paid at grant) as compensation for board service. These are grants (not open‑market purchases or sales).

Key Details

• Transaction date: June 5, 2026; Filing date (Form 4): June 9, 2026 (timely filed within the two‑business‑day window).
• Grants: 5,778 RSUs @ $0.00; 16,667 derivative units @ $0.00. Total units granted: 22,445.
• Vesting/settlement: Awards vest on the earlier of the first anniversary of the grant or immediately before the next annual meeting, subject to continued service. The Reporting Person has elected to defer settlement of the RSUs per an RSU Deferral Election adopted Oct 26, 2025.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No sales, purchases, or exercises reported here — this is compensation via equity grant.

Context

• RSUs and similar derivative awards represent a future right to receive shares if vesting conditions are met; they are compensation and do not represent immediate cash value until settled. The deferral election means settlement of vested RSUs will be delayed per the director’s election.
• These grants are routine board compensation and do not indicate an immediate market transaction (no shares were sold or bought in the open market).